Introduction
============

Although the status of the pelvic lymph node (LN) does not affect the International Federation Gynecology and Obstetrics (FIGO) clinical stage of cervical cancer, pelvic LN involvement is known to be among the most important adverse prognostic factors \[[@b1-roj-2017-00367]-[@b4-roj-2017-00367]\]. In invasive cervical cancer, lymphatic spread typically occurs in a stepwise progression. The pattern of nodal metastasis tends to be orderly in a contiguous and predictable manner, starting from the lower pelvis to the upper pelvis, followed by the para-aortic lymph node (PALN) \[[@b5-roj-2017-00367],[@b6-roj-2017-00367]\]. The regional pelvic LN becomes involved before the common iliac and para-aortic nodal chain. PALN metastases rarely occur in the absence of pelvic LN metastases. Although cervical cancer can metastasize to the common iliac and PALNs directly via the posterior cervical trunk, this pattern of spread is uncommon \[[@b7-roj-2017-00367],[@b8-roj-2017-00367]\]. Thus, patients with pelvic LN involvement are at risk for occult PALN metastasis.

In surgical series, clinically occult PALN involvement has been reported in up to 29% of patients \[[@b9-roj-2017-00367]\] and is more common in those with pelvic LN metastases \[[@b7-roj-2017-00367]\]. Surgical LN staging of locally advanced cervical cancer shows that the overall 12% rate of occult PALN metastasis increases to 22% in those with pelvic LN involvement \[[@b10-roj-2017-00367]\]. A phase III randomized trial reported that elective PALN radiotherapy can reduce paraaortic recurrence in these patients and improve survival \[[@b11-roj-2017-00367],[@b12-roj-2017-00367]\]. As such, prophylactic extended-field pelvic radiotherapy (EF-PRT), including the para-aortic region, has been suggested to treat occult metastases in locally advanced cervical cancer, particularly in patients with pelvic LN involvement. The rationale for EF-PRT is to sterilize micrometastatic disease and mitigate the risk of distant relapse.

However, most evidence supporting the clinical benefit of EF-PRT was derived from patients treated with radiotherapy (RT) alone before the era of platinum-based concurrent chemoradiotherapy (CCRT). The benefit of EF-PRT is unclear in concurrent platinum-based chemotherapy. As such, we conducted a retrospective study to determine the benefit of EF-PRT in patients with cervical cancer with pelvic LN involvement. This study aimed to evaluate whether EF-PRT yields better results than standard whole pelvic radiotherapy (WPRT) in patients with pelvic LN-positive cervical cancer treated with CCRT.

Materials and Methods
=====================

1. Patients
-----------

We retrospectively reviewed 310 cases of cervical cancer treated between 2000 and 2016 using definitive CCRT with a curative aim in our institution between 2000 and 2016. The inclusion criteria were as follows: (1) newly diagnosed histologically proven squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix; (2) clinical and radiologic FIGO stage IB-IVA with no other evidence of distant metastasis; (3) positive pelvic LN involvement on computed tomography (CT), magnetic resonance imaging (MRI), or fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) scan; (4) no evidence of PALN metastasis on imaging (MRI and PET/ CT scan); and (5) treatment using pelvic RT with platinum-based concurrent chemotherapy. The LNs were classified as metastatic based on radiographic findings (\>1.0 cm in the short axis dimension or presence of hypermetabolic activity) at the time of diagnosis or radiological and oncological interpretation of the appearance of the nodes. The PALN and pelvic LN were not surgically assessed. Patients with a history of hysterectomy, other malignancy, prior abdominal or pelvic RT, prior chemotherapy, or positive PALN metastasis diagnosed via imaging or biopsy were excluded.

Finally, 126 patients were enrolled for analysis and were divided into two groups: WPRT (i.e., RT of the entire pelvis) and EF-PRT (i.e., RT of the entire pelvis and PALN area for prophylaxis) ([Table 1](#t1-roj-2017-00367){ref-type="table"}).

2. Chemoradiotherapy
--------------------

All patients were scheduled to receive combined external beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT). EBRT was delivered with four fields (anteroposterior, posteroanterior, and two lateral fields) of 6--15 MV photons or with anteroposterior--posteroanterior opposed beams of 10--15 MV photons. The decision to use EF-PRT was at the discretion of the radiation oncologist, balancing the risk of occult paraaortic metastases against the potential for increased acute and late toxicity. Patients who had a common iliac LN metastasis were treated with EF-PRT or with WPRT that fully covered the common iliac nodal area just below aortic bifurcation. The superior border of EBRT was the L3-L4 (n = 20) or L4-L5 (n = 54) interspace depending on the location of aortic bifurcation or the presence of extensive pelvic LN involvement for WPRT. In EF-PRT, the superior border was extended to encompass PALN area according to the discretion of the radiation oncologist as follows: T12-L1 (n = 9), L1-L2 (n = 2), or L2-L3 (n = 41) interspace. In boost RT for enlarged LN area, three-dimensional conformal RT or intensity-modulated radiotherapy (IMRT) is used since 2009. All patients received a median EBRT dose of 45 Gy (range, 39.6 to 54 Gy) at 1.7 Gy or 1.8 Gy per fraction to the whole pelvic area and the boost RT of 9 Gy (range, 0 to 23.4 Gy) given at 1.8 Gy or 2 Gy per fraction to enlarged LN regions, involved parametrium, or involved regions of the pelvic side wall. The median dose to the PALN area in patients treated with EF-PRT was 45 Gy (range, 41.4 to 45.9 Gy) given at 1.7 or 1.8 Gy per fraction.

After adequate tumor regression, high-dose-rate ICBT was performed twice per week using an iridium-192 remote after-loading technique. The standard prescribed dose for each brachytherapy in our institution was 5.0 Gy to A-point in 6 fractions, twice weekly. The prescribed A-point dose was median 30 Gy (range, 25 to 36 Gy). The combined total dose from EBRT and ICBT was calculated using a linear quadratic model to determine the radiobiological equivalent dose in 2 Gy fractions (EQD2) (α/β = 10) \[[@b13-roj-2017-00367]\]. The mean total prescribed A-point EQD2 was 84.98 Gy. The prescribed dose for the target volume is given [Table 2](#t2-roj-2017-00367){ref-type="table"}. The median overall irradiated time was 59 days (range, 45 to 133 days).

Cisplatin-based chemotherapy was delivered concurrently with EBRT in all patients. During RT, chemotherapy with weekly cisplatin (40 mg/m^2^ weekly for 6 weeks) was given to 79 patients. During EBRT, two cycles of cisplatin-based combination chemotherapy with cisplatin plus 5-fluorouracil (5-FU) or cisplatin plus paclitaxel at 3-week intervals were given to 25 and 22 patients, respectively. Chemotherapy with cisplatin and 5-FU consisted of an intravenous infusion of 75 mg/m^2^ of cisplatin (day 1) followed by an intravenous infusion of 4,000 mg/m^2^ of 5-FU over a 96-hour period (days 2--5). A total of 1 L of normal saline was given both before and after cisplatin administration, and mannitol was used to increase urine output (day 1). Meanwhile, chemotherapy with cisplatin plus paclitaxel consisted of an intravenous infusion of 135 mg/m^2^ of paclitaxel (day 1) followed by an intravenous infusion of 75 mg/m^2^ of cisplatin (day 2).

Chemotherapy was started at the commencement of RT (day 1). Premedications included ondansetron and dexamethasone to reduce nausea and vomiting. If patients had grade 3 or 4 leukopenia or neutropenia, then granulocyte-macrophage colony-stimulating factor was used. The chemotherapeutic dose was reduced when patients had severe hematologic or non-hematologic toxicities. Chemotherapy was stopped when severe toxicities were persistent after dose reduction, when patients had poor performance status, or when patients refused the treatment.

3. Response evaluation and follow-up
------------------------------------

All patients were subjected to routine post-CCRT surveillance with physical examination, cervicovaginal cytology, laboratory test (e.g., squamous cell carcinoma antigen), and imaging studies, including abdominopelvic CT, MRI, and PET/CT. After completion of CCRT, the patients were evaluated every 3 months for the first 2 years and every 6 months thereafter. Recurrence was diagnosed through physical examination and diagnostic imaging (contrast-enhanced CT, MRI, and PET/CT scans) and was confirmed histologically via needle aspiration or excisional biopsy when possible. Patients were assessed for toxicity using the Common Terminology Criteria for Adverse Events version 4.0.

4. End points and statistical methods
-------------------------------------

The primary end point for treatment comparison was 5- and 10-year PALN recurrence rate, disease-free survival (DFS) rate, and overall survival (OS) rate. DFS was defined as survival without locoregional, PALN, or distant recurrences. In-field pelvic recurrence was defined as recurrent or progression of primary tumor, or pelvic (regional) LN failure in the irradiated pelvic region. We considered persistent cervical disease or enlarged pelvic LN that did not regress for 3 months after completion of RT as in-field pelvic recurrence. Distant metastasis was defined as recurrence outside the infrarenal para-aortic field. For disease event, we considered the first sites of recurrence as disease sites. We calculated all occurrences from the date of diagnosis to the date of relapse or the last date of follow-up. Deaths from other cause were censored at the time of last follow-up.

The chi-square test and Fisher exact test were used to analyze the differences between the groups with respect to several prognostic factors. The survival analysis was based on the Kaplan-Meier method, and the results were compared using the log-rank test. Treatment-related toxicities and recurrence rate were compared using Fisher exact test. All analyses were performed using SPSS ver. 19.0 (IBM, Armonk, NY, USA), and a p-value \<0.05 was considered statistically significant.

Results
=======

1. Patient characteristics
--------------------------

A total of 126 patients were eligible for analysis. Of them, 74 (58.7%) were treated with WPRT and concurrent chemotherapy, and 52 (41.3%) were treated with EF-PRT and concurrent chemotherapy. The majority of the patients (86.5%) presented with squamous cell carcinoma. The median age was 51 years (range, 23 to 81 years). The largest maximum diameter of primary tumor and short-axis diameter of metastatic pelvic LN in all patients was median 42 mm (range, 10 to 84 mm) and median 12 mm (range, 6 to 53 mm), respectively. Eight patients (6.35%) had an evidence of common iliac LN metastasis. Among the eight patients, six patients were treated with EF-PRT. Patient characteristics of the two treatment groups are given in [Table 1](#t1-roj-2017-00367){ref-type="table"}.

No significant differences were noted between the groups in terms of patient characteristics, including clinical stage, histological distribution, tumor diameter, metastatic LN size, and level of pretreatment squamous cell carcinoma antigen. Patients who received EF-PRT tended to have a slightly younger age than those who received WPRT, but the difference was not statistically significant (p = 0.066). The prescribed radiation dose was also not significantly different in both treatment groups, except the prescribed EBRT dose to the PALN area ([Table 2](#t2-roj-2017-00367){ref-type="table"}).

2. Clinical and survival outcomes
---------------------------------

The median follow-up time was 75.5 (range, 5 to 195 months), 76.5, and 79.3 months for all patients, for patients in the WPRT group, for those in the EF-PRT group, respectively. Treatment failure occurred in 37 patients (29.4%). Detailed patterns of failure are shown in [Table 3](#t3-roj-2017-00367){ref-type="table"}. In the EF-PRT group, PALN recurrence was observed in three patients (5.8%; two isolated out-of-field recurrence and one multiple recurrence of infield pelvic LN and in-field PALN). In the WPRT group, seven patients (9.5%) developed out-of-field PALN recurrence (five isolated out of field, two multiple recurrence of in-field pelvic LN and in-field PALN). The incidence of PALN recurrence was not significantly different between the treatment groups. The cumulative PALN recurrence rate as classified according to radiation field is shown in [Fig. 1](#f1-roj-2017-00367){ref-type="fig"}. For all patients, the 10-year cumulative PALN recurrence rate for EF-PRT vs. WPRT was 6.9% vs. 10.1% (p = 0.421), respectively. Fourteen patients (11.1%) failed systemically with a total of 16 sites. The most common site of distant metastasis was the lung (n = 9), followed by the mediastinal LN (n = 3), brain (n = 2), liver (n = 1), and supraclavicular LN (n = 1).

[Figs. 2](#f2-roj-2017-00367){ref-type="fig"} and [3](#f3-roj-2017-00367){ref-type="fig"} illustrate the Kaplan-Meier curves according to the radiation field. The 5- and 10-year DFS for EF-PRT vs. WPRT were 69.7% vs. 68.1% and 69.7% vs. 66.1% (p = 0.748), respectively. In addition, the 5- and 10-year OS for EF-PRT vs. WPRT were 77.3% vs. 75.5% and 71.7% vs. 72.3% (p = 0.845), respectively. The PALN recurrence rate (p = 0.421), PFS (log-rank, p = 0.748), and OS (log-rank, p = 0.845) in the WPRT group ([Figs. 1](#f1-roj-2017-00367){ref-type="fig"}--[3](#f3-roj-2017-00367){ref-type="fig"}, [Table 3](#t3-roj-2017-00367){ref-type="table"}) were not significantly different compared with those in the EF-PRT group.

3. Toxicity
-----------

A summary of acute and late toxicities is shown in [Table 4](#t4-roj-2017-00367){ref-type="table"}. The most common acute toxicities were gastrointestinal complications. Acute grade 1--3 gastrointestinal complications were significantly higher in the EF-PRT group (n = 21; 40.4%) than in the WPRT group (n = 26; 35.1%) (p = 0.046). There were no acute grade 4 complications. Although the difference did not reach statistical significance, the incidence of patients with acute toxicities in the EF-PRT group (26/52 patients, 50%) was higher than that in the WPRT group (31/74 patients, 41.9%) (p = 0.368). The event of neutropenia was observed 7 patients (9.5%) in the WPRT group and in 10 patients (19.2%) in the EF-PRT group, and neutropenia was resolved with medical management. There was no statistically significant difference about the incidence of neutropenia in both treatment groups (p = 0.114). Because of acute complications including neutropenia and/or concerns about a potential toxicity of treatment, 4 patients (5.4%) in the WPRT group and 10 patients (19.2%) in the EF-PRT group were treated with reduced dose of chemotherapeutic agent during CCRT. The dose reduction of chemotherapeutic agent during CCRT was observed significantly more in the EF-PRT group than in the WPRT group (p = 0.015). Due to toxicities that were persistent after dose reduction and poor performance status, only two patients (1 in the WPRT group and 1 in the EF-PRT group) stopped chemotherapy. Although overall grade 1--2 acute side effects were often observed during CCRT, they were usually self-limiting or resolved with medical management. In general, WPRT or EF-PRT plus concurrent cisplatin-based chemotherapy was well tolerated. All patients completed the planned EBRT.

Grade 3--4 severe late toxicities were observed in 15 patients (20.3%) in the WPRT group and in 15 patients (30.8%) in the EF-PRT group. Although the absolute percentage of late toxicities was lower in the WPRT group, the difference did not reach statistical significance (p = 0.178). Treatment-related late toxicities in each RT group are summarized in [Table 4](#t4-roj-2017-00367){ref-type="table"}, and their severity between the treatment groups was not different.

Discussion and Conclusion
=========================

Several randomized studies regarding EF-PRT in the pre-CCRT era have been published. EF-PRT alone had the potential to reduce PALN recurrence and improve survival. Haie et al. \[[@b14-roj-2017-00367]\] reported the results of the European Organization for Research and Treatment of Cancer Trial that compared the outcomes of two regimens of RT (i.e., EF-PRT vs. WPRT; 45 Gy) in 441 patients with cervical cancer who had no evidence of PALN involvement. No statistically significant difference was found between the two treatment arms with regard to local control, distant metastases, or survival. However, the incidence of para-aortic and distant metastases without pelvic failure was significantly high in patients receiving WPRT. The rate of severe complication was higher at 9% in patients receiving EF-PRT compared with 4.8% in those receiving WPRT. A similar randomized study was reported by Rotman et al. \[[@b12-roj-2017-00367]\]; they updated the results of the Radiation Therapy Oncology Group (RTOG) randomized trial of 337 cervical cancer patients with no evidence of PALN involvement who were randomized to electively receive or not 45 Gy to the PALN region. They found a significant difference in OS favoring the EF-PRT arm, although no difference in local recurrence and DFS was noted. The 10-year survival rate was 55% for patients receiving EF-PRT and 44% for those receiving WPRT (p = 0.02). The 10-year grade 4 or 5 complication rate was 8% in the group receiving EF-PRT and 4% in patients treated with WPRT (p = 0.06). These studies suggested that despite the high complication rates, EF-PRT had a clinical benefit in the pre-CCRT era.

Since 1999, CCRT has been the standard treatment for locally advanced cervical cancer based on the results of five phase III randomized clinical trials \[[@b15-roj-2017-00367]-[@b19-roj-2017-00367]\]. Since then, locally advanced cervical cancer was generally treated with WPRT with concurrent chemotherapy. Although a previous randomized controlled study demonstrated the superiority of WPRT plus concurrent chemotherapy over EF-PRT in patients with stage IB to IIB disease in the setting of definitive RT for cervical cancer \[[@b15-roj-2017-00367],[@b19-roj-2017-00367]\], WPRT plus concurrent chemotherapy has become a standard treatment for this patient population.

Although WPRT was not directly compared with EF-PRT in the CCRT setting, an RTOG 90-01 trial randomized patients with locally advanced cervical cancer to either WPRT with concurrent 5-FU and cisplatin or EF-PRT without concurrent chemotherapy. The study showed that OS and DFS were long in the CCRT arm, with 8-year rates of 41% and 67%, respectively \[[@b19-roj-2017-00367]\]. These results suggested that the use of concurrent chemotherapy with WPRT to some degree eradicate subclinical metastases beyond the field of RT. Nevertheless, the risk of PALN recurrence remains a concern given that WPRT with concurrent chemotherapy might not eliminate microscopic tumors in the PALN, particularly in patients with risk factors, including positive pelvic LNs. In clinical practice, due to concerns regarding toxicity, clinicians also face the dilemma of whether EF-PRT with concurrent chemotherapy should be applied to patients with locally advanced cervical cancer with positive pelvic LNs but negative PALN metastasis as shown on imaging modalities. In line with this, several institutions conducted a retrospective study regarding the feasibility and toxicity of EF-PRT with concurrent chemotherapy, and conflicting evidence regarding acute and late toxicity rates regarding CCRT with EF-PRT were reported \[[@b6-roj-2017-00367],[@b20-roj-2017-00367]-[@b24-roj-2017-00367]\].

In the CCRT era, evidence regarding the application of risk-based radiation field (WPRT vs. EF-PRT) for cervical cancer is conflicting. To our knowledge, only three retrospective studies and one prospective study that directly compared WPRT and EF-PRT in the CCRT setting for cervical cancer without evidence of PALN metastasis have been performed since 1999.

Park et al. \[[@b25-roj-2017-00367]\] evaluated the efficacy of EF-PRT in patients with locally advanced cervical cancer without PALN involvement. In their study, CCRT was administered to 133 of 203 patients (62 in EF-PRT, 71 in WPRT), and they reported that in patients treated with CCRT, differences in the treatment field had no significant effect on OS or DFS. Concurrently, Yap et al. \[[@b26-roj-2017-00367]\] reported the results of a retrospective study comparing the outcomes of two regimens of RT in 228 patients (73 patients in the EF-PRT group vs. 155 patients in the WPRT group) with locally advanced cervical cancer with no evidence of PALN involvement. In this study, all patients received external beam WPRT at a median dose of 50 Gy concurrent with weekly cisplatin, followed by a pulsed-dose rate ICBT. The para-aortic area either received or did not receive a median dose of 40 Gy. They reported that the addition of EF-PRT was not associated with a significant difference of DFS or OS on multivariate analysis, and no significant difference in the rate of PALN recurrence was noted in both groups with a median follow-up of 4.6 years. Among the 228 patients, the pelvic LN-positive cohort comprised 67 patients (29.4%; 46 patients in the EF-PRT treatment group and 21 patients in the WPRT treatment group). Looking at this subgroup separately, the addition of PALN RT had also no significant effect on DFS (hazard ratio \[HR\], 1.05; confidence interval \[CI\], 0.56--1.99; p = 0.95), OS (HR, 0.98; CI, 0.42--2.29; p = 0.96), or PALN recurrence rate (HR, 2.01; CI, 0.79--5.12; p = 0.21) \[[@b26-roj-2017-00367]\].

Meanwhile, other studies have reported the potential benefit of EF-PRT with concurrent chemotherapy. In a small randomized, prospective study, Asiri et al. \[[@b27-roj-2017-00367]\] showed that prophylactic EF-PRT with concurrent chemotherapy can be a reasonable option for patients with locally advanced cervical cancer with radiologically positive pelvic LN and radiographically negative PALN. Recently, Lee et al. \[[@b28-roj-2017-00367]\] reported a prophylactic lower para-aortic RT using IMRT with weekly cisplatin for FIGO stage IB2-IVA cervical cancer with negative PALN involvement. They reported that although the clinical outcome for patients with FIGO IBIIB and negative pelvic LN was not significantly different, the 5-year PALN recurrence-free survival and OS for WPRT vs. EF-PRT were 80.1% vs. 96.4% (p = 0.02) and 58.1% vs. 83.5% (p = 0.012), respectively, in patients with stage III-IVA or positive pelvic LN. They concluded that EF-PRT with IMRT and concurrent chemotherapy reduced PALN recurrence and improved OS without increasing the occurrence of severe toxicities for patients with locally advanced cervical cancer and positive pelvic LN or FIGO III-IVA disease. However, these nonrandomized studies had heterogeneity in tumor characteristics, and the patients in the EF-PRT group had more advanced disease in terms of tumor stage and positive pelvic LNs than those in the WPRT group. In the prospective study, they also had poor randomization, selection bias, and low sample size \[[@b27-roj-2017-00367]\]. Thus, in patients undergoing platinum-based CCRT, the role of EF-PRT has not been clearly established, particularly in the presence of pelvic LN involvement.

In this study, we assessed PALN recurrence rate, DFS, and OS in patients with pelvic LN-positive cervical cancer treated with concurrent chemotherapy plus EF-PRT or WPRT. Seven (9.46%) and 3 (5.77%) patients had PALN recurrence in the WPRT group and EF-PRT group (p = 0.522), respectively, and the 10-year cumulative PALN recurrence rate as classified according to the radiation field for the WPRT vs. EF-PRT was 10.1% vs. 6.9% (p = 0.421), respectively. Although a relatively high incidence of PALN failure was shown, the findings did not have statistical significance. As shown in [Figs. 2](#f2-roj-2017-00367){ref-type="fig"} and [3](#f3-roj-2017-00367){ref-type="fig"}, when the patients were treated with EF-PRT plus concurrent chemotherapy, no significant difference was noted in DFS and OS, indicating that the addition of EF-PRT to WPRT plus concurrent chemotherapy did not have a significant impact on the clinical outcome. We found that patients with pelvic LN-positive cervical cancer treated with cisplatin-based CCRT did not benefit from prophylactic EF-PRT. Our findings are consistent with those of Park et al. \[[@b25-roj-2017-00367]\] and Yap et al. \[[@b26-roj-2017-00367]\]. A recent meta-analysis regarding EF-PRT by Sapienza et al. \[[@b29-roj-2017-00367]\] reported that cancer-related death was not significantly altered (odds ratio, 0.68; CI, 0.45--1.01; p = 0.06), and the potential impact of PALN RT on survival warrants a reconsideration of EF-PRT. Collectively, these results of the present and previous studies indicate that the clinical benefit of EF-PRT with concurrent chemotherapy was limited.

The present study has some limitations. Our study was a retrospective analysis of the data from a single institution and thus could have a selection bias. Treatment strategy in terms of chemotherapy regimen and radiation field (the upper border of EF-PRT or WPRT) was not consistently controlled in all patient cohort. A relatively small patient number is also a weak point. Another limitation is retrospective data collection on complication. Based on all the medical records available in our institution, the toxicity results were described. Because this study was retrospective in nature and medical records were incomplete, we may have underestimated the toxicities. However, several important findings were obtained. The study was intended solely for cervical cancer patients with evidence of pelvic LN involvement. Although the study design was retrospective, patient characteristics in the two groups were not significantly different. The follow-up period was also appropriate. Based on these factors, this study provides additional evidence supporting the use of WPRT rather than EF-PRT in CCRT for cervical cancer with the evidence of pelvic LN involvement.

In conclusion, the present study suggests that EF-PRT does not have an additional benefit in patients with pelvic LN-positive cervical cancer treated with CCRT. Although pelvic LN involvement has a risk of occult PALN metastasis, no benefits of prophylactic PALN RT with concurrent cisplatin-based chemotherapy were noted. A well-designed prospective randomized study with a large patient cohort and multi-institutional participation is necessary to determine whether or not EF-PRT with concurrent chemotherapy improves the clinical outcomes compared with WPRT with concurrent chemotherapy and to evaluate the toxicity of EF-PRT with concurrent chemotherapy, particularly in patients with pelvic LN involvement.
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![Cumulative rate of para-aortic lymph node (PALN) recurrence as classified according to the radiotherapy field. The 10-year recurrence rate of PALN involvement: whole pelvic radiotherapy (WPRT) vs. extended-field pelvic radiotherapy (EF-PRT), 10.1% vs. 6.9%, respectively (p = 0.421).](roj-2017-00367f1){#f1-roj-2017-00367}

![Disease-free survival estimation using Kaplan-Meier analysis. The 5- and 10-year disease-free survival rate: whole pelvic radiotherapy (WPRT) vs. extended-field pelvic radiotherapy (EF-PRT), 68.1% and 66.1% vs. 69.7% and 69.7%, respectively (p = 0.748).](roj-2017-00367f2){#f2-roj-2017-00367}

![Overall survival estimation using Kaplan-Meier analysis. The 5- and 10-year overall survival rate: whole pelvic radiotherapy (WPRT) vs. extended-field pelvic radiotherapy (EF-PRT), 75.5% and 72.3% vs. 77.3% and 71.7%, respectively (p = 0.845).](roj-2017-00367f3){#f3-roj-2017-00367}

###### 

Patients' characteristics

  Variable                                                                          Whole pelvic radiotherapy (n = 74)   Extended-field pelvic radiotherapy (n = 52)   p-value
  --------------------------------------------------------------------------------- ------------------------------------ --------------------------------------------- ---------
  Age (yr)                                                                          54.5 (23--76)                        48 (32--81)                                   0.066
  Primary tumor diameter (mm)                                                       41 (10--70)                          46 (10--72)                                   0.112
  Metastatic pelvic LN size^[a)](#tfn1-roj-2017-00367){ref-type="table-fn"}^ (mm)   11.7 (6--53)                         13 (6--31.1)                                  0.501
   \<10                                                                             18                                   11                                            0.909
   ≥10 and \<20                                                                     47                                   34                                            
   ≥20                                                                              9                                    7                                             
  Metastatic pelvic LN number                                                       2 (1--6)                             2 (1--7)                                      0.130
  Stage                                                                                                                                                                
   IB1                                                                              16                                   5                                             0.411
   IB2                                                                              8                                    10                                            
   IIA1                                                                             3                                    1                                             
   IIA2                                                                             2                                    3                                             
   IIB                                                                              25                                   17                                            
   IIIB                                                                             16                                   14                                            
   IVA                                                                              4                                    2                                             
  Pathologic type                                                                                                                                                      
   SCC                                                                              63                                   46                                            
   Adenocarcinoma or ASCC                                                           11                                   6                                             
  Differentiation                                                                                                                                                      
   Well                                                                             1                                    1                                             0.433
   Moderately                                                                       70                                   46                                            
   Poorly                                                                           3                                    5                                             
  Pre-treatment SCC antigen level (ng/mL)                                           6.48 (0.5--65.29)                    7.4 (0.1--143)                                0.989
  Chemotherapy                                                                                                                                                         
   Weekly cisplatin                                                                 48                                   31                                            0.364
   Cisplatin + 5-FU                                                                 16                                   9                                             
   Cisplatin + paclitaxel                                                           10                                   12                                            

Values are presented as median (range) or number.

LN, lymph node; SCC, squamous cell carcinoma; ASCC, adenosquamous cell carcinoma; 5-FU, 5-fluorouracil.

The size of the metastatic pelvic LN was evaluated via CT and MRI, maximum short-axis dimension of metastatic LN.

###### 

Prescribed dose for the target volume (unit: cGy)

                                                       Whole pelvic radiotherapy (n = 74)   Extended field pelvic radiotherapy (n = 52)   p-value
  ---------------------------------------------------- ------------------------------------ --------------------------------------------- ---------
  Prophylactically prescribed EBRT EQD2 to PALN area   0                                    4,419.6 ± 56.0                                \<0.001
  Prescribed EBRT EQD2 to uninvolved pelvic LN area    4,423.9 ± 193.7                      4,516.1 ± 331.9                               0.076
  Prescribed EBRT EQD2 to enlarged pelvic LN area      5,262.6 ± 463.8                      5,234.3 ± 343.7                               0.709
  Prescribed EBRT EQD2 to cervical mass                4,783.9 ± 592.3                      4,832.6 ± 531.7                               0.636
  Prescribed brachytherapy EQD2 for A-point            3,711.5 ± 241.1                      3,600.7 ± 582.1                               0.200
  Total Prescribed A-point EQD2 (= EBRT + ICR)         8,495.4 ± 649.5                      8,433.3 ± 814.4                               0.636

Values are presented as mean ± standard deviation.

EBRT, external beam radiotherapy; EQD2, radiobiological equivalent dose in 2 Gy per fraction (α/β = 10); PALN, para-aortic lymph node; LN, lymph node.

###### 

Recurrence pattern according to radiation field

  Recurrence pattern                  Whole pelvic radiotherapy (n = 74)   Extended-field pelvic radiotherapy (n = 52)   p-value
  ----------------------------------- ------------------------------------ --------------------------------------------- --------------------------------------------------------
  In-field pelvic recurrence          11                                   5                                             0.384
  Para-aortic lymph node recurrence   7                                    3                                             0.522^[a)](#tfn2-roj-2017-00367){ref-type="table-fn"}^
  Distant recurrence                  6                                    8                                             0.201

Fisher exact test.

###### 

Radiation-induced acute and late complications

  Complication                                                          Whole pelvic radiotherapy (n = 74)   Extended field pelvic radiotherapy (n = 52)   p-value
  --------------------------------------------------------------------- ------------------------------------ --------------------------------------------- --------------------------------------------------------
  Acute complication^[a)](#tfn3-roj-2017-00367){ref-type="table-fn"}^   31 (41.9)                            26 (50)                                       0.368
   Genitourinary                                                                                                                                           
    Any                                                                 1 (1.4)                              4 (7.7)                                       0.152^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            0 (0)                                0 (0)                                         \-
   Gastrointestinal                                                                                                                                        
    Any                                                                 26 (35.1)                            21 (40.4)                                     0.046^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            2 (2.7)                              4 (7.7)                                       0.192^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Neutropenia                                                                                                                                             
    ≥Grade 3                                                            7 (9.5)                              10 (19.2)                                     0.114
  Late complication^[b)](#tfn4-roj-2017-00367){ref-type="table-fn"}^    15 (20.3)                            16 (30.8)                                     0.178
   Proctitis                                                                                                                                               
    Any                                                                 7 (9.5)                              7 (13.5)                                      0.627^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            7 (9.5)                              7 (13.5)                                      0.627^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Enteritis                                                                                                                                               
    Any                                                                 3 (4.1)                              4 (7.7)                                       0.446^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            1 (1.4)                              2 (3.8)                                       0.569^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Cystitis                                                                                                                                                
    Any                                                                 6 (8.1)                              7 (13.5)                                      0.331
    ≥Grade 3                                                            5 (6.8)                              6 (11.5)                                      0.359^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Rectovaginal fistula                                                                                                                                    
    Any                                                                 0 (0)                                1 (1.9)                                       0.413^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            0 (0)                                1 (1.9)                                       0.413^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Bowel obstruction                                                                                                                                       
    Any                                                                 0 (0)                                2 (3.8)                                       0.168^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            0 (0)                                2 (3.8)                                       0.168^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Lymphedema                                                                                                                                              
    Any                                                                 3 (4.1)                              1 (1.9)                                       0.642^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            3 (4.1)                              1 (1.9)                                       0.642^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
   Hydronephrosis                                                                                                                                          
    Any                                                                 3 (4.1)                              2 (3.8)                                       1.000^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^
    ≥Grade 3                                                            3 (4.1)                              2 (3.8)                                       1.000^[c)](#tfn5-roj-2017-00367){ref-type="table-fn"}^

Values are presented as number (%).

Some patients had multiple radiotherapy-induced complications.

Total number of patients with concurrent chemoradiotherapy-induced acute complications.

Total number of patients with radiotherapy-induced late complications.

Fisher exact test.
